NEW You can now listen to Fox News articles!

There may be a promising new treatment on the horizon for advanced breast cancer patients, according to developing research.

Researchers are studying the cancer-killing drug trastuzumab rezetecan for those with ERBB2-low metastatic breast cancer , whose tumors have low levels of HER2, a protein that can help cancer cells grow.

A phase 3 clinical trial called HORIZON-Breast06 sought to determine whether the drug works better than standard chemotherapy for patients with this cancer type.

SHIFT IN CANCER SCREENING GUIDANCE HAS EXPERTS CLASHING OVER NEW GUIDANCE

The researchers analyzed 551 female patients across 73 hospitals in China who were randomly assigned to receive either the drug intravenously every three weeks, or the physician’s choice of chemotherapy. The study period lasted from June 2023 to August 2025.

The median time without tumor growth on the drug was 16.4 months compared to 6.8 months with chemo.…